{"pmid":32348742,"pmcid":"PMC7194606","title":"Fetal Interventions in the Setting of COVID-19 Pandemic: Statement from the North American Fetal Therapy Network (NAFTNet).","text":["Fetal Interventions in the Setting of COVID-19 Pandemic: Statement from the North American Fetal Therapy Network (NAFTNet).","Am J Obstet Gynecol","Bahtiyar, Mert Ozan","Baschat, Ahmet","Deprest, Jan","Emery, Stephen","Goodnight, William","Johnson, Anthony","McCullough, Laurence","Moldenhauer, Julie","Ryan, Greg","Tsao, KuoJen","Van Mieghem, Tim","Wagner, Amy","Zaretsky, Michael","32348742"],"journal":"Am J Obstet Gynecol","authors":["Bahtiyar, Mert Ozan","Baschat, Ahmet","Deprest, Jan","Emery, Stephen","Goodnight, William","Johnson, Anthony","McCullough, Laurence","Moldenhauer, Julie","Ryan, Greg","Tsao, KuoJen","Van Mieghem, Tim","Wagner, Amy","Zaretsky, Michael"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348742","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.ajog.2020.04.025","keywords":["covid-19","sars-cov-2","fetal intervention","fetal therapy","prenatal diagnosis"],"topics":["Prevention"],"weight":1,"_version_":1666138495422300162,"score":9.490897,"similar":[{"pmid":32375144,"title":"Fetal Diagnosis and Therapy during the COVID-19 Pandemic: Guidance on Behalf of the International Fetal Medicine and Surgery Society.","text":["Fetal Diagnosis and Therapy during the COVID-19 Pandemic: Guidance on Behalf of the International Fetal Medicine and Surgery Society.","The COVID-19 pandemic has stressed patients and healthcare givers alike and challenged our practice of antenatal care, including fetal diagnosis and therapy. This document aims to review relevant recent information to allow us to optimize prenatal care delivery. We discuss potential modifications to obstetric management and fetal procedures in SARS-CoV2-negative and SARS-CoV2-positive patients with fetal anomalies or disorders. Most fetal therapies are time sensitive and cannot be delayed. If personnel and resources are available, we should continue to offer procedures of proven benefit, acknowledging any fetal and maternal risks, including those to health care workers. There is, to date, minimal, unconfirmed evidence of spontaneous vertical transmission, though it may theoretically be increased with some procedures. Knowing a mother's preoperative SARS-CoV-2 status would enable us to avoid or defer certain procedures while she is contagious and to protect health care workers appropriately. Some fetal conditions may alternatively be managed neonatally. Counseling regarding fetal interventions which have a possibility of additional intra- or postoperative morbidity must be performed in the context of local resource availability. Procedures of unproven benefit should not be offered. We encourage participation in registries and trials that may help us to understand the impact of COVID-19 on pregnant women, their fetuses, and neonates.","Fetal Diagn Ther","Deprest, Jan","Choolani, Mahesh","Chervenak, Frank","Farmer, Diana","Lagrou, Katrien","Lopriore, Enrico","McCullough, Laurence","Olutoye, Olutoyin","Simpson, Lynn","Van Mieghem, Tim","Ryan, Greg","32375144"],"abstract":["The COVID-19 pandemic has stressed patients and healthcare givers alike and challenged our practice of antenatal care, including fetal diagnosis and therapy. This document aims to review relevant recent information to allow us to optimize prenatal care delivery. We discuss potential modifications to obstetric management and fetal procedures in SARS-CoV2-negative and SARS-CoV2-positive patients with fetal anomalies or disorders. Most fetal therapies are time sensitive and cannot be delayed. If personnel and resources are available, we should continue to offer procedures of proven benefit, acknowledging any fetal and maternal risks, including those to health care workers. There is, to date, minimal, unconfirmed evidence of spontaneous vertical transmission, though it may theoretically be increased with some procedures. Knowing a mother's preoperative SARS-CoV-2 status would enable us to avoid or defer certain procedures while she is contagious and to protect health care workers appropriately. Some fetal conditions may alternatively be managed neonatally. Counseling regarding fetal interventions which have a possibility of additional intra- or postoperative morbidity must be performed in the context of local resource availability. Procedures of unproven benefit should not be offered. We encourage participation in registries and trials that may help us to understand the impact of COVID-19 on pregnant women, their fetuses, and neonates."],"journal":"Fetal Diagn Ther","authors":["Deprest, Jan","Choolani, Mahesh","Chervenak, Frank","Farmer, Diana","Lagrou, Katrien","Lopriore, Enrico","McCullough, Laurence","Olutoye, Olutoyin","Simpson, Lynn","Van Mieghem, Tim","Ryan, Greg"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32375144","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1159/000508254","keywords":["covid-19","fetal anomaly","fetal medicine","fetal surgery","fetoscopy","sars-cov-2","vertical transmission"],"topics":["Prevention"],"weight":1,"_version_":1666138496441516035,"score":87.04981},{"pmid":32427199,"pmcid":"PMC7232066","title":"Maternal Fetal Surgery During the COVID-19 Pandemic.","text":["Maternal Fetal Surgery During the COVID-19 Pandemic.","Am J Obstet Gynecol MFM","Crombleholme, Timothy M","Moise, Kenneth J Jr","32427199"],"journal":"Am J Obstet Gynecol MFM","authors":["Crombleholme, Timothy M","Moise, Kenneth J Jr"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427199","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ajogmf.2020.100144","topics":["Prevention"],"weight":1,"_version_":1667352728847777792,"score":77.50789},{"pmid":32330534,"pmcid":"PMC7172818","title":"Considerations for Scaling Down Fetal Echocardiography During the COVID-19 Pandemic.","text":["Considerations for Scaling Down Fetal Echocardiography During the COVID-19 Pandemic.","Can J Cardiol","Cardinal, Mikhail-Paul","Poder, Thomas G","Roy-Lacroix, Marie-Eve","Cavalle-Garrido, Tiscar","Vaujois, Laurence","Dallaire, Frederic","32330534"],"journal":"Can J Cardiol","authors":["Cardinal, Mikhail-Paul","Poder, Thomas G","Roy-Lacroix, Marie-Eve","Cavalle-Garrido, Tiscar","Vaujois, Laurence","Dallaire, Frederic"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330534","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.cjca.2020.04.016","topics":["Prevention"],"weight":1,"_version_":1666138494600216576,"score":69.82444},{"pmid":32298273,"pmcid":"PMC7161957","title":"The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study.","text":["The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study.","The new type of pneumonia caused by the SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) has been declared as a global public health concern by WHO. As of April 3, 2020, more than 1,000,000 human infections have been diagnosed around the world, which exhibited apparent person-to-person transmission characteristics of this virus. The capacity of vertical transmission in SARS-CoV-2 remains controversial recently. Angiotensin-converting enzyme 2 (ACE2) is now confirmed as the receptor of SARS-CoV-2 and plays essential roles in human infection and transmission. In present study, we collected the online available single-cell RNA sequencing (scRNA-seq) data to evaluate the cell specific expression of ACE2 in maternal-fetal interface as well as in multiple fetal organs. Our results revealed that ACE2 was highly expressed in maternal-fetal interface cells including stromal cells and perivascular cells of decidua, and cytotrophoblast and syncytiotrophoblast in placenta. Meanwhile, ACE2 was also expressed in specific cell types of human fetal heart, liver and lung, but not in kidney. And in a study containing series fetal and post-natal mouse lung, we observed ACE2 was dynamically changed over the time, and ACE2 was extremely high in neonatal mice at post-natal day 1~3. In summary, this study revealed that the SARS-CoV-2 receptor was widely spread in specific cell types of maternal-fetal interface and fetal organs. And thus, both the vertical transmission and the placenta dysfunction/abortion caused by SARS-CoV-2 need to be further carefully investigated in clinical practice.","PLoS One","Li, Mengmeng","Chen, Liang","Zhang, Jingxiao","Xiong, Chenglong","Li, Xiangjie","32298273"],"abstract":["The new type of pneumonia caused by the SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) has been declared as a global public health concern by WHO. As of April 3, 2020, more than 1,000,000 human infections have been diagnosed around the world, which exhibited apparent person-to-person transmission characteristics of this virus. The capacity of vertical transmission in SARS-CoV-2 remains controversial recently. Angiotensin-converting enzyme 2 (ACE2) is now confirmed as the receptor of SARS-CoV-2 and plays essential roles in human infection and transmission. In present study, we collected the online available single-cell RNA sequencing (scRNA-seq) data to evaluate the cell specific expression of ACE2 in maternal-fetal interface as well as in multiple fetal organs. Our results revealed that ACE2 was highly expressed in maternal-fetal interface cells including stromal cells and perivascular cells of decidua, and cytotrophoblast and syncytiotrophoblast in placenta. Meanwhile, ACE2 was also expressed in specific cell types of human fetal heart, liver and lung, but not in kidney. And in a study containing series fetal and post-natal mouse lung, we observed ACE2 was dynamically changed over the time, and ACE2 was extremely high in neonatal mice at post-natal day 1~3. In summary, this study revealed that the SARS-CoV-2 receptor was widely spread in specific cell types of maternal-fetal interface and fetal organs. And thus, both the vertical transmission and the placenta dysfunction/abortion caused by SARS-CoV-2 need to be further carefully investigated in clinical practice."],"journal":"PLoS One","authors":["Li, Mengmeng","Chen, Liang","Zhang, Jingxiao","Xiong, Chenglong","Li, Xiangjie"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298273","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1371/journal.pone.0230295","locations":["placenta"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493312565248,"score":69.46485},{"pmid":32161408,"pmcid":"PMC7096028","title":"Lack of maternal-fetal SARS-CoV-2 transmission.","text":["Lack of maternal-fetal SARS-CoV-2 transmission.","Nat Med","Stower, Hannah","32161408"],"journal":"Nat Med","authors":["Stower, Hannah"],"date":"2020-03-13T11:00:00Z","year":2020,"_id":"32161408","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1038/s41591-020-0810-y","link_comment_for":"32151335","topics":["Transmission"],"weight":1,"_version_":1666138492659302401,"score":67.83321}]}